Ignite Creation Date:
2025-12-24 @ 7:11 PM
Ignite Modification Date:
2025-12-27 @ 2:37 PM
Study NCT ID:
NCT00441103
Status:
COMPLETED
Last Update Posted:
2014-07-09
First Post:
2007-02-26
Is NOT Gene Therapy:
True
Has Adverse Events:
True
Brief Title:
A Study to Evaluate Rebif® New Formulation (Interferon-beta-1a) in Relapsing Remitting Multiple Sclerosis
Sponsor:
Merck KGaA, Darmstadt, Germany
Organization:
Organization Data
Organization:
Class:
INDUSTRY
Study ID:
27178
Study Type:
None
Study Domain:
None
Study Link:
None
Lead Sponsor:
Lead Sponsor Class:
INDUSTRY
Responsible Party:
Responsible Party Title:
Responsible Party Type:
SPONSOR
Responsible Party Affiliation:
Old Name:
None
Old Organization:
None